Medicago in vaccine MOU in Japan

Medicago (TSX-V: MDG) has signed a memorandum of understanding with Japan’s NITT Partners to discuss and negotiate an agreement to commercialize Medicago’s pandemic and seasonal influenza VLP-based vaccines in Japan and other territories.

For several years, NITT Partners has been the government-approved technology transfer/licensing organization to license-in state of the art technologies. Under the terms of the MOU, the parties will evaluate and select an optimal deal structure with the objective of formalizing a definitive agreement.

“The successful completion of our Phase 1 clinical trial for our H5N1 vaccine candidate has opened additional global doors and has also advanced the ongoing discussions with our potential partners,” Medicago VP of business development Frederic Ors said in a statement.

“As we advance the clinical development of our vaccine candidates, we will continue to discuss opportunities with other pharmaceutical companies and governments to roll-out our compelling influenza vaccine technology around the globe,” he added.